OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:23 UTC. Every row links to its source record.

GNAS GNAS complex locus

ENSG00000087460 · protein coding · Open Targets profile

Guanine nucleotide-binding proteins (G proteins) function as transducers in numerous signaling pathways controlled by G protein- coupled receptors (GPCRs) (PubMed:12391161, PubMed:17110384, PubMed:21488135, PubMed:26206488, PubMed:8702665, PubMed:10200251). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (PubMed:12391161, PubMed:17110384, PubMed:10200251). Signaling by an activated GPCR promotes GDP release and GTP binding (PubMed:12391161, PubMed:17110384, PubMed:10200251). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (PubMed:12391161, PubMed:17110384, PubMed:10200251). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:12391161, PubMed:17110384, PubMed:10200251). Signaling involves the activation of adenylyl cyclases, resulting in increased levels of the signaling molecule cAMP (PubMed:17110384, PubMed:26206488, PubMed:26206488, PubMed:8702665). Functions downstream of beta- adrenergic receptors (PubMed:21488135). Stimulates the Ras signaling pathway via RAPGEF2 (PubMed:12391161). {ECO:0000269|PubMed:10200251, ECO:0000269|PubMed:12391161, ECO:0000269|PubMed:17110384, ECO:0000269|PubMed:21488135, ECO:0000269|PubMed:26206488, ECO:0000269|PubMed:8702665}.

In 14 of 15 cancers, the evidence for GNAS comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751pituitary adenoma 3, multiple typespituitary adenoma 3, multiple typespituitary adenoma 3, multiple types: somatic 0.78pituitary adenoma 3, multiple types: germline 0.89pancreatic adenocarcinomapancreatic adenocarcinomapancreatic adenocarcinoma: somatic 0.81colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61sex cord-stromal tumorsex cord-stromal tumorsex cord-stromal tumor: somatic 0.68hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.51pancreatic ductal adenocarcinomapancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma: somatic 0.61myxomamyxomamyxoma: somatic 0.61pancreatic neoplasmpancreatic neoplasmpancreatic neoplasm: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61pseudomyxoma peritoneipseudomyxoma peritoneipseudomyxoma peritonei: somatic 0.61pyloric gland adenomapyloric gland adenomapyloric gland adenoma: somatic 0.61growth hormone-producing pituitary glan…growth hormone-producing pituitary gland adenomagrowth hormone-producing pituitary gland adenoma: somatic 0.61bile duct papillary neoplasmbile duct papillary neoplasmbile duct papillary neoplasm: somatic 0.61colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

No positive tractability buckets.

gnomAD loss of function constraint: o/e 0.14674000442028046 (upper bound 0.26475998759269714). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of GNAS's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of GNAS's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.